论文部分内容阅读
Aim of study:Evaluate its reliability by counterevidence study on coronary heart disease with phlegm-stasis cementation syndrome induced by combing coronary artery balloon-injury with high-lipid diet in Chinese mini-swines.Material and methods:24 Chinese mini-swines were randomly divided to four groups:normal control group,model group,Danlou tablet group,Shengmai capsule group,and six each in every group.After all animals except normal control group had been fed with high-fat diet for 2 weeks,Chinese mini-swines were induced to injury left anterior descending artery by interventional balloon injury,and subsequently continued to feed high-fat diet for 8 weeks to establishment of model with phlegm-stasis cementation syndrome of coronary heart disease.The hemorheological parameters,serum lipid levels,the myocardial ischemic limit and myocardial infarct area were measured at the end of the study.The coronary artery stenosis and tongue feature were also observed.Results:Compared with normal control group,the blood viscosity at SS-1 and 60S-1,serum lipid levels,the myocardial ischemic limit and myocardial infarct area,and coronary artery stenosis was significantly increased at the end of study in model group,meanwhile RGB in tongue feature were also abnormal.Danlou tablet could decrease the blood viscosity at SS-1 and 60S-1,serum lipid levels,the myocardial ischemic limit and myocardial infarct area,and coronary artery stenosis.Danlou tablet also could improve RGB in tongue feature.Shengmai capsule had no more than Danlou tablet in reduction of blood viscosity at SS-1,VLDL-C,the myocardial ischemic limit and myocardial infarct area and coronary artery stenosis.Conclusion:According to syndrome differentiation and treatment,we conclude that the coronary heart disease with phlegm-stasis cementation syndrome in Chinese mini-swine has reliability by counterevidence study of Danlou tablet and Shengmai capsule.Meanwhile,the advantage of Chinese traditional medicine can be successfully performed only under the guidance of syndrome differentiation and treatment.